

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 18 APR 2001

WIPO

PCT

Applicant's or agent's file reference DC-0120	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/26610	International filing date (day/month/year) 10 November 1999 (10.11.1999)	Priority date (day/month/year) 30 November 1998 (30.11.1998)
International Patent Classification (IPC) or national classification and IPC IPC(7): C12Q 1/68; C07H 21/04 and US Cl.: 435/6; 536/23.1		
Applicant TRUSTEES OF DARTMOUTH COLLEGE		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer <b>TERRY J. DEY</b> Jeanine Enewold Goldberg, <b>PARALEGAL SPECIALIST</b> Telephone No. (703) 308-1196 <b>TECHNOLOGY CENTER 1600</b>

Form PCT/IPEA/409 (cover sheet)(July 1998)

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/26610

## I. Basis of the report

### 1. With regard to the **elements** of the international application: \*

- ☒ the international application as originally filed.
- ☒ the description:
  - pages 1-13 \_\_\_\_\_ as originally filed
  - pages NONE \_\_\_\_\_, filed with the demand
  - pages NONE \_\_\_\_\_, filed with the letter of \_\_\_\_\_.
- ☒ the claims:
  - pages 14 \_\_\_\_\_, as originally filed
  - pages NONE \_\_\_\_\_, as amended (together with any statement) under Article 19
  - pages NONE \_\_\_\_\_, filed with the demand
  - pages NONE \_\_\_\_\_, filed with the letter of \_\_\_\_\_.
- ☐ the drawings:
  - pages NONE \_\_\_\_\_, as originally filed
  - pages NONE \_\_\_\_\_, filed with the demand
  - pages NONE \_\_\_\_\_, filed with the letter of \_\_\_\_\_.
- ☒ the sequence listing part of the description:
  - pages 1-5 \_\_\_\_\_, as originally filed
  - pages NONE \_\_\_\_\_, filed with the demand
  - pages NONE \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

### 2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

### 3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

### 4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages none
- ☒ the claims, Nos. none
- ☒ the drawings, sheets/fig none

### 5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)). \*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/26610

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>1-5</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>1-5</u>	YES
	Claims <u>NONE</u>	NO
Industrial Applicability (IA)	Claims <u>1-5</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS (Rule 70.7)**

Claims 1-5 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest a method of diagnosing a matrix metalloproteinase-1 related disease in a patient comprising detecting in the patient matrix metalloproteinase-1 containing the Ets transcription factor binding site single nucleotide polymorphism.

----- NEW CITATIONS -----

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the questions whether the claims are fully supported by the description, are made:

Claims 1-5 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not enabled as required under PCT Rule 5.1(a) for the reasons set forth in the immediately preceding paragraph.

The claims are broadly drawn to a method of diagnosing or prognosticating a matrix metalloproteinase-1 related disease by detecting the matrix metalloproteinase-1 (MMP-1) containing the Ets transcription factor binding site single nucleotide polymorphism. The claims are also drawn to methods of identifying therapeutic agents for treatment of a MMP-1 related disease.

The specification teaches MMP-1 is associated with irreversible degradation of cartilage, tendon and bone in arthritis, degradation of collagenase I and III in tumor invasion and metastasis (pg. 1). Furthermore, the specification teaches that patients with tumors that express MMP-1 have a poor prognosis than patients with tumors that do not express this protein (pg. 2). The specification teaches that the full length DNA sequence with only 1 G at position -1607 constitutes a SNP (pg. 3). The specification teaches that while the SNP is not located in the coding region and does not alter the structure of the enzyme, it has profound effect on the production/regulation of the enzyme (pg. 4). The specification further teaches a study in which 100 hundred control DNA's were sampled to determine the frequency of the variation in the population (pg. 8). The specification teaches that the frequency of the 2G homozygotes in the controls was approximately 30% whereas the frequency in tumor cell lines was 62.5% ( $p < 0.0001$ ) (pg. 8). The specification provides several explanations which may explain the differences in expression such as growth factor and cytokines, specific nuclear factors within the cell (pg. 9).

The art teaches the a DNA sequence of the MMP-1 which only contained 1G at position -1607 (Rutter et al. J. Cell Biochem. 66: 322-336, 1997)(pg. 2). The art also teaches the sequence where 2Gs are located at this position (pg. 2). The consensus sequence for a functional PEA3/EBS is provided in Graves (J.B. Science 279: 1000-1001, 1998).

It would be undue experimentation for the skilled artisan to practice the invention as broadly as claimed. The assertion that the MMP-1 EBS-SNP in patients is indicative of the patient suffering from a disease relating to overexpression of the MMP-1 enzyme is not supported by any clinical studies that provide this correlation. While the specification teaches that the frequency of the 2G homozygotes is expressed more frequency in tumor cell lines, this does not provide enablement for a method of diagnosing a MMP-1 related disease based upon the identification of the SNP. The study does not provide any data taken from patients with MMP-1 diseases, but rather amplex cell lines. Cell lines are not representative of individuals with MMP-1 related diseases. Secondly, the specification does not identify any specific disease which have been shown to be associated with the 2G polymorphism in the MMP-1. It would be undue experimentation for the skilled artisan to perform clinical studies to associate the single nucleotide polymorphism with a MMP-1 related disease. Additionally, the specification provides several plausible explanations as to the difference in expression. Thus, it is unpredictable whether the 2G polymorphism is associated with MMP-1 diseases or whether extrinsic factors affect the expression and disease characteristics.

**Methods of Diagnosing, Prognosticating and Treating Matrix  
Metalloproteinase-1 Related Diseases via a Matrix  
Metalloproteinase-1 Single Nucleotide Polymorphism**

**INTRODUCTION**

5        This invention was made in the course of research sponsored by the National Institutes of Health. The U.S. Government may have certain rights in this invention.

**BACKGROUND OF THE INVENTION**

10        Matrix metalloproteinases (MMPs) are a family of at least 15 enzymes that degrade the extracellular matrix (ECM) (Borden, P. and Heller, R. Crit. Rev. Eukaryotic Gene Expr. 7: 159-178, 1997). These enzymes have essential roles in modeling and remodeling the ECM in normal physiology and  
15 disease pathology. Several of these enzymes have the unique ability to degrade the interstitial collagenase (types I, II, and III), the body's most abundant proteins. MMP-1 is the most ubiquitously expressed interstitial collagenase, thereby assigning it a prominent role in collagen degradation.  
20 Overexpression of MMP-1 is associated with several pathological conditions, including the irreversible degradation of cartilage, tendon, and bone in arthritis (Vincenti et al. Crit. Rev. Eukaryotic Gene Expr. 6:391-411, 1996) and the degradation of collagenase I and III in tumor  
25 invasion and metastasis (Chambers, A.F. and Matrisian, L.M. J. Nat'l Cancer Inst. 89:1260-1270, 1997; Murray et al. Nat.

Med. 2:461-462, 1996). Patients with tumors that express MMP-1 have an overall poorer prognosis than patients with tumors that do not express this protein (Murray et al. Nat. Med. 2:461-462, 1996; Murray et al. J. Pathol. 185:256-261, 1998).

5 This overexpression of MMP-1 has been suggested to be due to the juxtaposition of transcription factor binding sites within the promoter of this gene and to the cooperativity among the factors that bind these sites (Buttice et al. Oncogene 13:2297-2306, 1996; Basuyaux et al. J. Biol. Chem. 272:26188-

10 26195, 1997; Gutman, A. and Waslyk, B. EMBO J. 9:2241-2246, 1990; Benbow, U. and Brinckerhoff, C.E. Matrix Biol. 15:519-526, 1997).

Most normal cells express modest, but detectable, levels of MMP-1 constitutively, and this expression increases

15 substantially in the presence of cytokines or growth factors (Vincenti et al. Crit. Rev. Eukaryotic Gene Expr. 6:391-411, 1996; Rutter et al. J. Cell Biochem. 66:322-336, 1997; Aho et al. Eur. J. Biochem. 247:503-510, 1997; Delany, A.M. and Brinckerhoff, C.E. J. Cell Biochem. 50:400-410, 1992).

20 However, A2058 melanoma cells constitutively express high levels of MMP-1 (Templeton et al. Cancer Res. 50:5431-5437, 1990), making them a useful model for studies on the transcriptional regulating of this gene and for comparative studies with normal cells.

25 A 4 kb region of the MMP-1 promoter DNA from a leukocyte genomic library was isolated and sequenced (Rutter et al. J. Cell Biochem. 66:322-336, 1997). DNA sequence analysis revealed that this clone contained only 1 G at position -1607 bp, resulting in the sequence 5'-AAGAT-3' (SEQ ID NO: 1)

30 (Rutter et al. J. Cell Biochem. 66:322-336, 1997). This sequence differs from that reported by others (Aho et al. Eur. J. Biochem. 247:503-510, 1997; Imai et al. Mol. Cell Biol. 14:7182-7194, 1994), wherein 2 Gs at that location which create the sequence 5'-AAGGAT-3' (SEQ ID NO: 2) are

35 described. The presence of 2 Gs at this site creates the

- 3 -

sequence 5'-GGA-3', which is a consensus sequence (Graves, J.B. Science 279:1000-1001, 1998) for a functional PEA3/EBS. This site has now been established to constitute a single nucleotide polymorphism (SNP). The full length DNA sequence  
5 of MMP-1 with only 1 G at position -1607 is depicted in SEQ ID NO: 3.

Based upon the effect of this SNP on the transcriptional activity, protein/DNA binding activity, and frequency of this SNP in normal fibroblasts and in melanoma tumor cells it has  
10 now been determined that detection of this SNP is useful in diagnosing and prognosticating cancer and other MMP-1 related diseases. It is also now believed that agents identified as inhibitors of binding of transcription factors to the Ets transcription factor binding site created by or resulting from  
15 this SNP will be useful in treating MMP-1 related diseases.

#### SUMMARY OF THE INVENTION

An object of the present invention is to provide a method of diagnosing MMP-1 related diseases in a patient which comprises detecting in a patient MMP-1 containing an Ets  
20 transcription factor binding site single nucleotide polymorphism (MMP-1 EBS-SNP).

Another object of the present invention is to provide a method of prognosticating MMP-1 related diseases in a patient which comprises detecting in a patient suffering from  
25 an MMP-1 related disease an MMP-1 EBS-SNP.

Another object of the present invention is to provide a kit for diagnosis and prognosis of an MMP-1 related disease in a patient via detection of MMP-1 EBS-SNP in a patient sample.

30 Another object of the present invention is to provide a method of identifying agents with potential therapeutic value in treating MMP-1 related diseases which comprises screening agents for the ability to inhibit the binding of a transcription factor to an MMP-1 EBS-SNP.

- 4 -

Yet another object of the present invention is to provide a method of treating MMP-1 related diseases in a patient which comprises administering to the patient an agent which inhibits binding of a transcription factor to an MMP-1  
5 EBS-SNP.

#### DETAILED DESCRIPTION OF THE INVENTION

The abundance of single nucleotide polymorphisms (SNPs) in the genome make these genomic variations powerful tools for  
10 identifying disease genes, particularly in loss of heterozygosity studies in tumors. A large effort is presently underway for identifying SNPs. Most research is focused on the coding regions of genes (Wang et al. Science 280:1077-1082, 1998).

15 However, an SNP located in the promoter of the interstitial collagen degrading enzyme, MMP-1, has now been identified. Because this variation is not located in a coding region, it does not alter the structure of the enzyme. However, the location of this SNP in the promoter region of  
20 MMP-1 has now been demonstrated to have profound effects on the production/regulation of the enzyme. Further, an increase in the frequency of this SNP in tumor cell lines has now been demonstrated which is indicative of this SNP causing an  
25 expression. MMP-1 is implicated in tumor cell invasion and metastasis due to its ability to cleave the interstitial collagenase types I and III at neutral pH. Therefore, a structural variation with the potential to influence the level of expression is important to understanding how this enzyme  
30 modulates ECM metabolism and tumor cell invasion and metastasis. Further, detection of this SNP in a patient is useful in diagnosing and prognosticating MMP-1 related diseases.

The effects of this SNP, referred to herein as MMP-1  
35 EBS-SNP, on the transcriptional activity and protein/DNA



binding activity, along with the frequency of this SNP in normal fibroblasts and in melanoma tumor cells were examined in detail.

Constitutive mRNA expression of endogenous MMP-1 gene in normal foreskin fibroblasts (HFS) and in the A2058 melanoma cells over a 24 hour period was determined. HFS expressed low levels of MMP-1 mRNA, while A2058 cells expressed higher levels. To determine whether the A2058 cells contained a difference in the endogenous MMP-1 promoter, polymerase chain reaction (PCR) was used to amplify the promoter from these cells. This sequence was then compared with the previously isolated leukocyte clone described by Rutter et al. *J. Cell Biochem.* 66:322-336, 1997 and set forth in SEQ ID NO: 3 and with promoters from other sources (Aho et al. *Eur. J. Biochem.* 247:503-510, 1997; Imai et al. *Mol. Cell Biol.* 14:7182-7194, 1994). Several substitutions were observed, but were considered insignificant because they did not create or delete any known binding sites for transcription factors within the promoter. However, one major difference was detected: the A2058 promoter DNA contained an additional G at position -1607 bp, which was flanked by a guanidine (5') and an adenine (3'), thus creating an Ets transcription factor binding site (EBS; Graves, *B. Science* 279:1000-1001, 1998).

To specifically test the role of the 1 G/2 G variation in regulating transcription, two luciferase reporter constructs driven by a large (4.3 kb) fragment of the MMP-1 promoter were generated with the only difference being 1 G or 2 Gs at -1607 bp. This SNP is adjacent to an AP-1 site -1602 bp, which may also influence transcription. These clones were transiently transfected in HFS and the effect on basal transcription was measured. A significant increase (ranging from 2-10-fold) in transcription with the 2 G promoter construct compared with the 1 G promoter construct was consistently observed in at least four separate donors of HFS. Hirt's analysis of transfected DNA demonstrated that these

differences were not attributable to transfection efficiency. When these two constructs were transfected into the A2058 melanoma cells, a 29-fold increase in transcription of the 2 G construct over the 1 G construct was observed. Other experiments showed similar increases ranging from 1- to 37-fold. These constructs were then tested in other tumor cell lines (MDA231 breast cancer cells, and two primary melanoma lines) to assess their transcriptional response. In these cells, the 2 G promoter construct augmented transcription at least 4-fold over the 1 G construct. Thus, the increase in transcription is dependent on the presence of 2 Gs at -1607 bp, and it is seen in both normal and malignant cells.

The ability of an oligo probe containing either 1 G or 2 Gs at -1607 bp to bind to nuclear extracts from the A2058 cells was also assessed. A striking difference in binding intensity was seen, with the 2 G oligo binding more nuclear proteins compared with the 1 G oligo. Thus, the presence of the 2 Gs clearly augments this binding. Cross competition experiments were used to determine the specificity of binding to each labeled oligo. Binding to the 1 G oligo was readily competed, suggesting that these DNA/protein interactions are weak. Competition studies with the 2 G oligo revealed that the "self" oligo only mildly competed the binding of the shared bands, although it did compete two bands, demonstrating that these proteins bind preferentially and/or specifically to the 2 G oligo. Furthermore, the 1 G oligo did not compete well, but was effective in competing the shared bands. Finally, the proximal EBS-AP-1 competitor showed a pattern similar to that seen with the 1 G oligo. Taken together, these observations indicate that the 2 G "self" oligo competes for the proteins able to bind specifically to the 2 gene sequence, and that the other bands represent proteins or protein complexes that are not 2 G-dependent (e.g. the AP-1 proteins). Importantly, these data also indicate that the

- 7 -

presence of the EBS in this region of MMP-1 creates an environment where DNA/protein interactions strongly occur.

Because the SNP at -1607 bp is located adjacent to an AP-1 site at -1602 bp, binding to the 1 G and 2 G oligos by recombinant ETS-1 and c-JUN, proteins that are likely candidates for binding to these sites, was investigated. The recombinant proteins, by themselves, were not able to bind to either oligo. The combination of both proteins, however, bound to the 2 G oligo, but only faintly to the 1 G oligo, suggesting that additional proteins were required for optimal DNA binding. Indeed, incubation with nuclear extract from A2058 cells resulted in distinctive binding patterns for each probe. Complexes I, II, VI, and VII were present in both panels, whereas complexes III, IV, and V were specific for the 2 G oligo. When ETS-1 and c-JUN were added together with nuclear extract, binding to the 2 G oligo was more pronounced compared with the 1 G oligo.

In the presence of recombinant c-JUN, complex I became more apparent with both oligos, indicating that complex I may represent AP-1 proteins binding to the DNA. Complex VII also became more intense when c-JUN was added indicating that it, too, contains AP-1 related proteins. When both recombinant proteins were added, the binding pattern in the 1 G panel did not differ from the reactions with c-JUN alone, supporting the importance of 2 Gs in creating the EBS. When nuclear extracts and recombinant ETS-1 were added to the 2 G oligo, a new complex was formed (complex IV). Furthermore, when both proteins and nuclear extract were added to the 2 G probe, several complexes (I, III, IV, V, and VI) were diminished and seemed to combine into a much stronger complex II, again demonstrating the influence of the 2 Gs in creating EBS.

Antibodies to several members of the Ets family of transcription factors (ETS-1/2, Erg-1/2, Elk-1 and ERM) were used in "super/shift" reactions to identify the proteins binding to this site. However, binding of these antibodies

was not detected due either to limitations of the antibodies, because the complexes did not allow for the antibody to have access to the epitope, and/or because these proteins did not bind. These data suggest that the oligos containing 2 Gs  
5 represents a bona fide EBS that binds an Ets family member(s) in a complex with AP-1 protein members. While the data show that recombinant ETS-1 binds, it is believed that other Ets family members can also bind to this site.

Confirmation of this 1 G/2 G difference in the leukocyte  
10 clone sequence and the A2058 melanoma sequence, to be a SNP and not a mutation, was performed. A radiolabeled PCR assay using primers that flank the variation to amplify a product of either 148 bp (1 G), 149 bp (2 G), or both (heterozygous) in genomic DNA was developed. One hundred control DNAs  
15 derived from the CEPH pedigrees (<http://www.cephb.fr/cephdb/>) were then assayed to determine the frequency of this variation within a population. Only the parents in the pedigrees were used to avoid biasing the results through inheritance. In addition to the CEPH control DNAs, the frequency of this SNP  
20 in several tumor cell lines, including the A2058 melanoma cells, was assessed. The occurrence of 2 G homozygotes in the CEPH controls was determined to be approximately 30%. In the tumor cells lines, it is 62.5% ( $P < 0.0001$ ).

Accordingly, based upon these experiments, it is  
25 believed that the 1 G/2 G SNP influences the transcriptional responsiveness of the human MMP-1 promoter in cancer, where excessive production of MMP-1 is a major contributor to the stromal degradation involved in tumor invasion. As with other genes, expression of MMP-1 is mediated by multiprotein  
30 complexes that bind to DNA in a sequence-specific manner, and these complexes often cooperate to achieve maximal activation. DNA elements containing a single EBS are often not sufficient for Ets induction, and require a nearby AP-1 site to which Fos and JUN proteins bind. Furthermore, the transcriptional  
35 environment within the cells may influence the level of gene

expression, as evidenced by differences in the level of transcription of the 2 G allele in HFS versus melanoma cells. These differences may be due to various extracellular stimuli, such as growth factors and cytokines, as well as cell-type-specific nuclear factors within the cell. Thus, the combination of cis-acting sequences in the MMP-1 promoter and specific trans-acting factors can dramatically increase transcription. This increase is believed to provide a molecular mechanism for enhanced ECM degradation not only in cancer, but in other MMP-1 related diseases such as arthritis, cardiovascular disease and periodontitis.

For example, rheumatoid arthritis, a chronic disease that afflicts more than two million individuals in the United States and 1% of the population world-wide is characterized by severe and irreversible degradation of cartilage, tendon and bone mediated by overexpression of MMPs. Inflammatory cytokines such as interleukin-1 and tumor necrosis factor- $\alpha$  activate synovial fibroblasts that line the joint and adjacent chondrocytes to produce these MMPs. Destruction of interstitial collagen occurs mainly through two MMP family members, MMP-1 and MMP-13. MMP-1 and MMP-13 are expressed by synovial fibroblasts and articular chondrocytes. It is believed that, in similar fashion to patients suffering from cancer, overexpression of MMP-1 in patients suffering from rheumatoid arthritis may result at least in part from this SNP.

Accordingly, detection of the MMP-1 EBS-SNP in a patient provides a useful means for diagnosing MMP-1 related diseases. Detection of MMP-1 EBS-SNP in a patient is indicative of the patient suffering from a disease relating to overexpression of the MMP-1 enzyme. Detection of this SNP can be performed in accordance with well known techniques including, but not limited to, PCR as described herein.

Detection of MMP-1 EBS-SNP also provides a useful method for prognosticating MMP-1 related diseases in a patient. For

- 10 -

example, it is well known that MMPs are key players in tumor invasion and metastasis. Both processes require degradation of the extracellular matrix, which is accomplished by proteolytic enzymes that are secreted by either tumor cells, themselves, and/or neighboring stromal cells. In fact, at least for melanoma cells which produce MMP-1, the prognosis of the disease is correlated with tumor thickness and depth of invasion through dermal collagens (I and II), thereby indicating that invasiveness through these collagens serves as a valid prognostic marker. Accordingly, detection of MMP-1 EBS-SNP, which is indicative of enhanced ability to degrade collagen types I, II and III, in tumor cells of a patient serves as a useful prognostic marker in assessing the invasiveness of a particular tumor. This prognostic marker is thus useful in determining various treatment regimes expected to be most successful in individual patients.

Means for detecting MMP-1 EBS-SNP in a patient sample for diagnosing and/or prognosticating MMP-1 related diseases can be incorporated into a kit for easy use by a laboratory technician. In one embodiment, the kit can comprise PCR primers such as those described in Example 5 herein which flank the MMP-1 EBS SNP. In this embodiment, the kit may also comprise dGTP, dATP, dTTP, and dCTP; Taq DNA polymerase; and  $\alpha(32)\text{P}$ -dCTP. However, other means for detecting the MMP-1 EBS-SNP which can be incorporated into a kit will be obvious to those of skill in the art upon this disclosure. Kits of the present invention may also comprise positive and negative control samples.

Further, inhibiting MMP-1 synthesis by targeting either the MMP-1 EBS-SNP or proteins that bind to this SNP represents a useful therapeutic approach to inhibit pathologic expression of MMP-1, but not its normal physiological role. Potential therapeutic agents for treatment of MMP-1 related diseases including, but not limited to, cancer, rheumatoid arthritis, cardiovascular disease and periodontitis, can be identified

by determining their ability to either bind to MMP-1 EBS-SNP, to bind to proteins which bind to MMP-1 EBS-SNP or to inhibit binding of MMP-1 EBS-SNP with other proteins. Agents identified by this method can then be administered to patients suffering from an MMP-1 related disease to alleviate the symptoms resulting from overexpression of MMP-1.

The following nonlimiting examples are provided to further illustrate the present invention.

#### EXAMPLES

##### 10 Example 1: Cells and Plasmids

Primary human foreskin fibroblasts (HFF) were prepared in accordance with procedures described by Rutter et al. J. Cell Biochem. 66:322-336, 1997, and used during passages 4-8. HFFs and A2058 cells were cultured in DMEM (Life technologies, Inc.) with 10% fetal bovine serum (Sigma Chemical Co.), penicillin (100 units/ml), and streptomycin (100 µg/ml).

A 4.3-kb MMP-1 promoter DNA fragment containing only 1G at -1607 bp was described by Rutter et al. J. Cell Biochem. 66:322-336, 1997. Primers were made to amplify the endogenous promoter from the A2058 cells (-4008 bp to -3988 bp sense primer: 5'-GTGGAAGCTTACACCTATAATCCCAACACTC-3' (SEQ ID NO: 4) and -511 bp to -543 bp antisense primer: 5'-CTGCCTGGTACCCTATTGCGATAGCACCATGGC-3' (SEQ ID NO: 5). Two A2058 PCR amplified clones were subcloned into the pBL5CAT (Promega) vector and sequenced to ensure the absence of PCR artifacts. Reporter clones were then constructed in which the only difference between the two pGL3-MMP-1 vectors was the SNP at position -1607 bp. First, the MMP-1 promoter insert from the pXP2 vector was subcloned into the pGL3 Basic vector (Promega). Unique sequences flanking the G variation were restricted by AatII (5') and EcoRV (3'), thereby isolating a 450/451-bp fragment from the leukocyte clone in pGL3 Basic (1 G) and A2058 melanoma DNA in pBL5CAT (2 Gs), respectively, and excluding any other sequence variations found in the A2058 promoter. Finally, the 451-bp insert containing the 2 Gs was

"swapped" and ligated into the pGL3-MMP-1 construct containing AatII/EcoRV ends, thereby generating the two SNP constructs.

#### **Example 2: Northern Analysis**

Confluent cultures in 150-mm diameter tissue culture  
5 dishes were washed and placed in 10 ml of serum-free DMEM plus  
0.2% lactalbumin hydrolysate. Immediately (time 0) and at 24  
hours, total RNA was isolated using the TRIzol reagent (Life  
Technologies, Inc.) and 20 µg were subjected to Northern  
analysis and hybridized with cDNA-specific probes for MMP-1  
10 or glyceraldehyde-3-phosphate dehydrogenase. Probes were  
random prime labeled with  $\alpha(32)\text{P}$ -dCTP (12.5 µCi/reaction of  
3,000 Ci/mmol) and hybridized for 20 hours at 56°C.

#### **Example 3: Transfection and Luciferase Assay**

Transient transfections were performed in triplicate in  
15 accordance with procedures described by Rutter et al. J. Cell  
Biochem. 66:322-336, 1997 with the LipofectAMINE PLUS reagent  
(Life Technologies, Inc.) using 2 µg of the chimeric MMP-1  
promoter/reporter plasmids, 5 µl of the PLUS reagent, and 5  
µl of LipofectAMINE. Luciferase activity is reported as RLUs.  
20 Hirt's analyses were performed and normalized to RLUs to  
control for any variations in transfection efficiency.  
Statistics were performed using the InStat Program (GraphPad  
Software) using the Welch's alternate t test, a modification  
of the unpaired t test.

#### **Example 4: Nuclear Extract Preparation and EMSAs**

Extracts of nuclear proteins were prepared, and EMSAs  
were performed as described by Schroen, D.L. and Brinckerhoff,  
C.E. J. Cell Physiol. 169:320-332, 1996, with  $1 \times 10^5$  cpm of  
 $\gamma^{32}\text{P}$ -ATP end-labeled oligo incubated with nuclear extract (5  
30 µg) and/or recombinants ETS-1 protein (2 µM) and c-JUN protein  
(1 µg; Promega). The samples were subjected to 5% PAGE at 150  
V, dried, and autoradiographed. Oligos used for EMSAs were



- 13 -

1G sense, 5'-AAATAATTAGAAAGATATGACTTATCTCAAATCAA-3' (SEQ ID NO: 6); 2 G sense, 5'-AAATAATTAGAAAGGATATGACTTATCTCAAATCAA: (SEQ ID NO: 7) -88/-73 sense, 5'-TTCATTGTTAATCAAGAGGATGTTATAAAGCATGAGTCACACCCTCAGCTT-3' (SEQ ID NO: 8). The -88/-73 oligo spans the region -110 to -61 bp and includes the locations within the oligo that correspond to the proximal PEA3/AP-1 sites at the -88/-73, respectively.

**Example 5: Radiolabeled PCR Assay**

Primers that flank the SNP in MMP-1 were used for PCR amplification (sense primer, 5'-GTTATGCCACTTAGATGAGG-3' (SEQ ID NO: 9); antisense primer 5'-TTCCTCCCCTTATGGATTCC-3' (SEQ ID NO: 10)). A typical reaction consisted of ~20 ng of DNA template; 0.2 mM dGTP, dATP, and dTTP, 2.5  $\mu$ M dCTP; 10 x buffer and Taq DNA polymerase (Sigma Chemical Co.); and  $\alpha$ (32)P-dCTP (DuPont/NEN). Reactions were PCR amplified (MJ Research PTC100 THERMOCYCLER) in 25 cycles (4 minutes at 94°C; 45 seconds at 94°C, 45 seconds at 58°C, and 45 seconds at 72°C; followed by a brief extension (10 minutes) at 72°C). Following amplification, the reactions (2.5  $\mu$ l) were mixed with 10 X loading buffer and denatured for 2 minutes at 80°C. Samples were loaded onto an 8% denaturing PAGE and electrophoresed for 3 hours. Gels were dried and autoradiographed for approximately 15 minutes. Control samples generated from the plasmid clones were loaded on each gel for accurate scoring of the alleles. Statistics were calculated using the InStat Program (GraphPad Software) and were based on the percentage of the total number tested.

What is claimed is:

1. A method of diagnosing a matrix metalloproteinase-1 related disease in a patient comprising detecting in the patient matrix metalloproteinase-1 containing the Ets transcription factor binding site single nucleotide polymorphism.
2. A method of prognosticating a matrix metalloproteinase-1 related disease in a patient suffering from a matrix metalloproteinase-1 related disease comprising detecting in the patient matrix metalloproteinase-1 containing the Ets transcription factor binding site single nucleotide polymorphism.
3. A kit for diagnosing and prognosticating MMP-1 related diseases in a patient sample comprising a means for detecting matrix metalloproteinase-1 containing the Ets transcription factor binding site single nucleotide polymorphism in a patient sample.
4. A method of identifying potential therapeutic agents for treatment of a matrix metalloproteinase-1 related disease comprising determining a potential therapeutic agent's ability to inhibit binding of a transcription factor to an Ets transcription factor binding site of single nucleotide polymorphism matrix metalloproteinase-1.
5. A method of treating patients suffering from a matrix metalloproteinase-1 related disease comprising administering to the patient an agent which inhibits binding of a transcription factor to an Ets transcription factor binding site of single nucleotide polymorphism matrix metalloproteinase-1.

WO 00/3281

09/856749  
53 Rec'd PCT/ 24 MAY 2001  
PCT/US99/26610

SEQUENCE LISTING

<110> Brinckerhoff, Constance

Rutter, Joni

Trustees of Dartmouth College

<120> Methods of Diagnosing, Prognosticating and Treating  
Matrix Metalloproteinase-1 Related Diseases via a  
Matrix Metalloproteinase-1 Single Nucleotide  
Polymorphism

<130> DC-0120

<140>

<141>

<150> 60/110,266

<151> 1998-11-30

<160> 10

<170> PatentIn Ver. 2.0

<210> 1

<211> 5

<212> DNA

<213> Homo sapiens

<400> 1

aagat

5

<210> 2

<211> 6

<212> DNA

<213> Homo sapiens

<400> 2

aaggat

6

<210> 3

<211> 4438

<212> DNA

<213> Homo sapiens

<400> 3

cctcacatat ttcaaattcca tctcaaattc acattcacag atgtaagagc tgggaaagga 60  
cggttttgac agggctgaac tgagctatgg tatgagtagc actcatcccc agaaagtctc 120  
ttggtttgaa ttccgggaa aaggagctat agctgcaaaa atctgtttca caaatgtgct 180

aactataagc attttccaca gtgtttaata aaccatgcag ataagaaaat attattgaca 240  
aacaataata taaaatgctc aaaataatct gatactaaat gctttagca tggcatgcaa 300  
atcaccaaaa ataatgtgc tatgttcat ataaaatctc cagtaaggct ggggtgtgtg 360  
gctcacacct ataateccaa cactctggga ggccgagggt agagaaactgc ttgaggccag 420  
gagtttgaga ctgacctggc caacatagtg agacctcatc tctacaaaa atcttaaaaa 480  
tcagtgggac atggtggtgc acatctgtag ttctagctac ttgggagtct gaggcaggaa 540  
gattgcttaa gccaagagt ttgaggctcc taccctccag cctaagcgac agaggagac 600  
cttgcctcta aataaataaa ttagttaatt gaatgtccag tcagttgata tatccaaatt 660  
cttcccatgg taattttaaa aacttttagtc ttaggagagt aaaagtcagc gacataagac 720  
ttcttataaa caactcagcc taatgagaaa tagacctgt atttaagtgt catttaagta 780  
tctatttctt cattgatcta ttcatttatt aactcctgta acaatcattt gcagacacct 840  
actatgttga ggtagtataa actataaatt caacaagttt gataagggaa ataagagaga 900  
ttgagtgcaca gcttgaaggg gaggtattctt tcaggcctgt gggaccgggt ggtggcatgg 960  
agacattatt gtggacttga gggagttaat gtgacagtc tcgtgtctcc agacactttc 1020  
tctctgttag ggaagcaaga tttctatccc cagagtatgt atgtgttatg tctggactgc 1080  
agtggcacag aactgtgttc aacgagtgac taccgctctg ctgtgtgccc tgggacttgg 1140  
gggttaattga tcaatcattt ctatccagaa ggtaaccatg aggactgacg gaaccagtgt 1200  
gtaccaagtgt tctgttaagt gtctgggtcaa tgggtatcca taaagctact gcattggccat 1260  
atgttaggaag aatacacacc gtgagcaaat ttttcccacg tgtaactctc acaacaaaat 1320  
agcattaaat acttaatgtt tctggctaaa gaccatttca agacttgacg gacaaaaaaa 1380  
tagaaaaaat atctgacact caaatggagt taaaaaatta aaacgggtga attccccagc 1440  
ataaaaaaat atgaagcaag attgaaattt caagactaag tttaatatgg aaaaatacaa 1500  
atatgtttga ggcctttcac agagcagcca gcattgaagca accaagaaaa ccacggaaat 1560  
aatctggctg cctggaaata gtccggagtc agctgacaca gccacacgag agccctctta 1620  
tgcttgtcat aaggggtaaa ggaataattt cagaaaatta catttaaaaag agaattatgg 1680  
gggaagaaga tgctcccaga ggaaacaaat agtatggatg tgaagagcaa atacaacttt 1740  
aacatgtttt gaacttcttg gaaactatgc taagtttagg cattgctagg atttgggtatg 1800  
atttaatccc cagctttctg ttctaaattt ttgttttctt ttttactctc aaataaatca 1860  
tatgctagca ccagctgcaa agttacatat gttgtattag acgatcttcc atgaatacct 1920  
aactggaaat tccaagattc agggccatgt gaacttaggc tggctgttta accaaaactt 1980  
aatttaattt tttctgttta ttttaggaaa aaaaattaac gaaaagatgt ttcaagcaac 2040  
cagtttccaa tccacgtcag caactatgac atttaatgaa aactgtgag catttagcat 2100  
gagagctctg gactcagatg cagggagctt tgctagagaa gggaggaaaa agcaggcatg 2160  
atgtggcggg ttgtggggga ctccaaggct ctatttccaa ctcccatcag agaacttctg 2220  
ttttcacctg gttttcaaat ttgttttcca aaagggtatt tgtttaagta aaggatacag 2280  
aggtttataa aagtttgaaa acttctacat tgcaggatgt gcaggctctt gccagatggg 2340  
acagtgtatg agactcttcc agggtgacgt cttaggcaat ttctgttcca atcacagatg 2400  
gtcacatgct gctttcctga gttaacctat taactcacc ttgtttccca ggcctcagtg 2460  
gagctaggct tgtcacgtct tcacagtgc tagattccct cacagtcgag tatatctgcc 2520  
actccttgac ttttaaaaca tagtctatgt tcacctcta atatgaagag cccctttcac 2580  
tattttcttt gtctgtgctg gagtcacttc agtggcaagt gttctttggg ctctgccgca 2640  
ccctccctct gatgcctctg agaagaggat ttccttttct tgagaatgtc ttcccattct 2700  
tcttaccctc ttgaactcac atgttatgcc acttagatga ggaaattgta gttaaataat 2760  
tagaaagata tgacttatct caaatcaatc caagatatac tgaagtattg ttttagagta 2820  
agatatcagt cttgacgcag aaagaaaaca ggaatccata aggggaggaa agtggtgaaa 2880  
agcaaacctg atacagtggg aaagggtggga gacaccataa ggtgctgaag tgataaaaca 2940  
ggccagtgtt tctccactgt atgttttcaa taaatgcttc caaggaagga gagtggggca 3000  
tgagttagggg agctacagag ataaaccaac ttttcttacc aggaatgcta cagatagcac 3060

tgggtgacacc ggtcaccagt acccaagaca atttaatgtg gaacataagt acaggaatac 3120  
 acatctttca ttacagagcc atgtatttat tttaatgggc aggagatgct aaataagatc 3180  
 ttttgaatgg aggaatgcat aaatatatga atgaatgcat acatgaaaga ataaataaat 3240  
 gctgcctagc accaaggagc gaagatagac tcataatcaag ggaaacaagt atgattaaaa 3300  
 ataagacccc agagtcacgc tcagtctctt tccagccttt tcatcatccg gtacattcag 3360  
 acaagtttca ggggaaggatc ctatttggtc catgataatg atgggcaagg ggtggggagt 3420  
 tatctcatatc tccgctgtg gatgaggggt cttctcaggt aaggtcttta aatcctaggc 3480  
 ctgagtaaat tttttcaaat tttatttttag acagggtccc tctctgttgc ctaggctgga 3540  
 gtgcagcggc acaatcacag ctcaatgcag cctcaacctc ccaggcccaa gtgatcctcc 3600  
 cacctcagcc tcttcagtga ctaggactac aggtgcatga ctccatgctt ggctaacttt 3660  
 aaaaaatggt tgtttgtttg tttgtttttt acagagatgg ggtctcacca tgttgcccag 3720  
 gctgatcttg aactcctggg ctcaagtgat tcccctgcct cggcctcctg aaattctggg 3780  
 attataggct tgagccacca tgcttggtc tgagtaaaga ttaagggag ccatgggtgct 3840  
 atcgcaatag ggtaccaggc agcttaacaa aggcagaagg gaacctcaga gaaccccgaa 3900  
 gagccaccgt aaagtgagtg ctgggggagc tgaacttcag tcagtacagg agccgaacag 3960  
 ccacaggtg cgcagtgtta gtaattccac cctctgcctt gggagcaagg tgtgtggaga 4020  
 aacctgtagc actttatgac catcagaacc agcctttttc aaaaagacca tggagtactc 4080  
 ttgacctgt gtatataaca agaacctttc tcaaatagga aagaaatgaa ttggagaaaa 4140  
 ccactgttta catggcagag tgtgtctcct tcgcacacat cttgtttgaa gttaatcatg 4200  
 acattgcaac accaagtgt tccaaataat ctgctaggag tcaccatttc taatgattgc 4260  
 ctagtctatt catagctaata caagaggatg ttataaagca tgagtcagac acctctggct 4320  
 ttctggaagg gcaaggactc tatatataca gagggagctt cctagctggg atattggagc 4380  
 agcaagaggc tgggaagcca tcacttacct tgcactgaga aagaagacaa aggccagt 4438

&lt;210&gt; 4

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Synthetic

&lt;400&gt; 4

gtggaagctt acacctataa tcccaacact c

31

&lt;210&gt; 5

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Synthetic

&lt;400&gt; 5

ctgcctggta ccctattgag atagcaccat ggc

33

&lt;210&gt; 6

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Synthetic

&lt;400&gt; 6

aaataattag aaagatatga cttatctcaa atcaa

35

&lt;210&gt; 7

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Synthetic

&lt;400&gt; 7

aaataattag aaaggatatg acttatctca aatcaa

36

&lt;210&gt; 8

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Synthetic

&lt;400&gt; 8

ttcattgtta atcaagagga tgttataaag catgagtcac accctcagct t

51

&lt;210&gt; 9

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Synthetic

&lt;400&gt; 9

gttatgccac ttagatgagg

20

&lt;210&gt; 10

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

WO 00/3281

PCT/US99/26610

<223> Description of Artificial Sequence: Synthetic

<400> 10

ttcttccct tatggattcc

20

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : C12Q 1/68, C07H 21/04	A1	(11) International Publication Number: <b>WO 00/32819</b> (43) International Publication Date: 8 June 2000 (08.06.00)
<p>(21) International Application Number: PCT/US99/26610</p> <p>(22) International Filing Date: 10 November 1999 (10.11.99)</p> <p>(30) Priority Data: 60/110,266 30 November 1998 (30.11.98) US</p> <p>(71) Applicant (for all designated States except US): TRUSTEES OF DARTMOUTH COLLEGE [US/US]; Technology Transfer Office, 11 Rope Ferry Road #6210, Hanover, NH 03755-1404 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BRINCKERHOFF, Constance, E. [US/US]; 7 Falcon Lane, Norwich, VT 05055 (US); RUTTER, Joni, L. [US/US]; Bailey Road, Thetford, VT 08074 (US).</p> <p>(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).</p>	<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report.</p>	
<p>(54) Title: METHODS OF DIAGNOSING, PROGNOSTICATING AND TREATING MATRIX METALLOPROTEINASE-1 RELATED DISEASES VIA A MATRIX METALLOPROTEINASE-1 SINGLE NUCLEOTIDE POLYMORPHISM</p> <p>(57) Abstract</p> <p>Methods and kits for diagnosing and prognosticating matrix metalloproteinase-1 related disease by detecting a single nucleotide polymorphism in the promoter of the gene are provided. Also provided are methods of identifying agents which inhibit binding of transcriptions factors to the Ets transcription factor binding site created by or resulting from this single nucleotide polymorphism and methods of using these agents to treat matrix metalloproteinase-1 related diseases.</p>		